Preview

Russian Journal of Cardiology

Advanced search

Comparative analysis of antihypertensive effects of chlorthalidone and indapamide-retard in combination with azilsartan medoxomil in patients with arterial hypertension

https://doi.org/10.15829/1560-4071-2019-6-122-130

Abstract

Achievement of target blood pressure (BP) is one of the key strategies of primary prevention of cardiovascular complications in patients with arterial hypertension (AH).

Aim. To assess and compare antihypertensive effects of azilsartan medoxomil (AZM) with chlorthalidone or indapamide-retard combination in patients with AH in real clinical setting.

Material and methods. The open randomized comparative study included 50 patients with uncontrolled AH who were randomized to the starting therapy with combination of AZM with chlorthalidone (Edarbi Clo 40/12,5 mg) (group 1) or indapamide-retard 1,5 mg (group 2) for 4 weeks. After 4 weeks, up-titration of one of the drugs was done in the patients who didn’t achieve target BP level (<140/<90 mm Hg): chlorthalidone from 12,5 mg to 25 mg in G1 and AZM from 40 to 80 mg in group 2. Duration of the study was 12 weeks. Treatment efficacy was assessed by the target office BP achievement and changes in 24-h peripheral and central BP. Results were considered statistically significant at p<0,05.

Results. At the end of the 12-week period target BP was achieved in 88% of group 1 and 72% of group 2 patients. According to 24-h blood pressure monitoring (ABPM) mean peripheral BP decline was 19,3/11,1 vs 17,1/9,1 mm Hg for 24h, 20,1/11,4 vs 19,1/9,9 mm Hg for daytime, 19,5/9,1 vs 17,6/8,9 mmHg for nighttime (p<0,05 for trend). Target 24-h BP levels <130/<80 mm Hg were achieved in 40 vs 32% of patients respectively (р<0,05). Increase of the portion of dippers was observed from 60 to 64% and from 58 to 62% respectively (p<0,05).

Conclusion. In patients with uncontrolled AH combination of AZM with chlorthalidone compared has led to more pronounced antihypertensive effect compared to combination of AZM with indapamide-retard.

About the Authors

Zh. D. Kobalava
Peoples’ Friendship University of Russia
Russian Federation

Moscow.


Competing Interests: Nothing to declare


V. V. Kulakov
Almazov National Medical Research Center
Russian Federation

St. Petersburg.


Competing Interests: Nothing to declare


L. A. Goreva
Peoples’ Friendship University of Russia
Russian Federation

Moscow.


Competing Interests: Nothing to declare


S. V. Villevalde
Almazov National Medical Research Center
Russian Federation

St. Petersburg.


Competing Interests: Nothing to declare


References

1. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39 (33):3021-104, doi:101093/eurheartj/ehy339.

2. Kobalava ZD, Villevalde SV. Azilsartana Medoxomil: a New Possibilities in the Treatment of Hypertension. Pharmacological Properties. Kardiologiia 2014;12:57-62. (In Russ.) doi:10.18565/cardio.2014.12.57-62.

3. Bakris G, Sica D, White W, et al. Antihypertensive efficacy of hydrochlorothiazide vs chlorthalidone combined with azilsartan medoxomil. Am J Med. 2012;125:1229e1-1229e10. doi:10.1016/j.amjmed.2012.05.023.

4. Ernst M, Neaton J, Grimm R, et al. Long-term effects of chlorthalidone versus hydrochlorothiazide on electrocardiographic left ventricular hypertrophy in the multiple risk factor intervention trial. Hypertension. 2011;58:1001-7. doi: 10.1161/HYPERTENSIONAHA.111.181248.

5. Ernst M, Carter B, Goerdt C, et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension. 2006;47:352-8. doi:10.1161/01.HYP.0000203309.07140.d3.

6. Gorbunov VM. 24-hour blood pressure monitoring: modern aspects. M.: Logosphera, 2015. 240 p. (In Russ.)

7. Sever P, Messerli F. Hypertension management 2011: optimal combination therapy. Eur Heart J 2011 ;32 (20):2499-506. doi:10.1093/eurheartj/ehr177.

8. Muromtseva GA, Kontsevaya AV, Konstantinov VV, et al. The prevalence of non-infectious diseases risk factors in Russian population in 2012-2013 years. The results of ECVD-RF. Cardiovascular Therapy and Prevention 2014; 13 (6):4-11. (In Russ.) doi:10.15829/1728-8800-2014-6-4-11.

9. SPRINT Research Group: Wright J., Williamson J., Whelton P. et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373 (22):2103-16. doi:10.1056/NEJMoa1511939.

10. Karpov Yu.A. Fixed-drug combination of azilsartan medoxomil/chlorthalidone — new possibilities in blood pressure control in arterial hypertension. Atmosphere. Cardiology news. 2016;1:39-44 (In Russ.)

11. Kobalava ZD, Villevalde SV, Kulakov VV. Antihypertensive Efficacy of Fixed Combination Azilsartan Medoxomil/Chlorthalidone in Patients With Uncontrolled Arterial Hypertension. Kardiologiia. 2017;57 (11): 12-8. (In Russ.) doi:10087/cardio.2017.11.10049.

12. Sica D, White W, Weber M, et al. Comparison of the novel angiotensin II receptor blocker azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoring. J Clin Hypertens (Greenwich). 2011;13 (7):467-72. doi:10.1111/j.1751-7176.2011.00482.x.

13. White W, Cuadra R, Lloyd E, et al. Effects of azilsartan medoxomil compared with olmesartan and valsartan on ambulatory and clinic blood pressure in patients with type 2 diabetes and prediabetes. J Hypertens. 2016;34 (4):788-97 doi: 10.1097/HJH.0000000000000839.

14. Bonner G, Bakris G, Sica D, еt al. Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril. J Hum Hypertens. 2013;27:479-86. doi:10.1038/jhh.2013.6.

15. Skibitskiy VV, Fendrikova AV, Sirotenko DV, et al. Chronotherapeutic aspects of the efficacy of combination treatment with azilsartan medoxomil in patients with arterial hypertension and metabolic syndrome. Kardiologiia. 2016;10:35-40. (In Russ.).


Review

For citations:


Kobalava Zh.D., Kulakov V.V., Goreva L.A., Villevalde S.V. Comparative analysis of antihypertensive effects of chlorthalidone and indapamide-retard in combination with azilsartan medoxomil in patients with arterial hypertension. Russian Journal of Cardiology. 2019;(6):122-130. (In Russ.) https://doi.org/10.15829/1560-4071-2019-6-122-130

Views: 18529


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1560-4071 (Print)
ISSN 2618-7620 (Online)